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Introduction: Reliable and precise measurement of patient adherence to medications is
feasible by incorporating a microcircuitry into pharmaceutical packages of various designs,
such that the maneuvers needed to remove a dose of drug are detected, time-stamped,
and stored.The principle is called “electronic medication event monitoring” but is currently
limited to the monitoring of a single drug therapy.
Aim: Our aims were introducing a new technology; a clear, self-adhesive polymer ﬁlm,
with printed loops of conductive wires that can be afﬁxed to multidrug punch cards for
the electronic adherence monitoring of multiple medication regimens (Polymedication
Electronic Monitoring System, POEMS), and illustrating potential beneﬁts for patient care.
We present a preliminary report with one patient experience.
Materials and methods: Our illustrative case was supplied with a pre-ﬁlled 7-day multiple
medication punch card with unit-of-use doses for speciﬁc times of the day (six pills in
the morning cavity, two pills in the evening cavity, and one pill in case of insomnia in the
bedtime cavity), with the new electronic ﬁlm afﬁxed on it.
Results: The intake times over 1 week were extremely skewed (median intake hours at
2:00 pm for the morning doses and at 6:40 pm for the evening doses). After an intervention
aimed at optimizing the timing adherence, the morning and evening intake hours became
more balanced, with 42.3% of correct dosing intervals (±3 h) for drugs with twice daily
intake (vs. 0% before the intervention).
Discussion: The electronic monitoring of the entire therapy revealed an intake pattern
that would have remained undiscovered with any other device and allowed a personalized
intervention to correct an inadequate medication intake behavior. POEMS may guide
health professionals when they need to optimize a pharmacotherapy because of suspected
insufﬁcient adherence. Further, knowing the intake pattern of the entire pharmacotherapy
can elucidate unreached clinical outcome, drug–drug interactions, and drug resistance. In
the near future, one could imagine that medication adherence data over the entire therapy
plan would be available as soon as the electronic wires are activated, so that a failure to take
medication could be detected immediately and intervention could be taken if appropriate.
Keywords: compliance, adherence, electronic monitoring, multidrug punch card, printed electronics, community
pharmacy
INTRODUCTION
The idealmeasurement of adherence has long since been described
(Rudd, 1979; Pullar and Feely, 1990) and should be non-invasive,
unobtrusive (to avoid that the drug-taking behavior of the patient
is inﬂuenced by the device), objective (to generate reproducible
data for each subject), reliable (to insure that the prescribed
dose was really taken at the time of package opening), practical
and cheap (to maximize use and minimize costs). It should also
yield immediate results and not be open to manipulation. Based
on these stringent requirements, traditional, indirect measures
(i.e., which do not demonstrate drug ingestion, such as self-
reporting, medication diaries, residual pill counting, pharmacy
records, and clinician opinion) do satisfy many criteria (Laufs
et al., 2011). However, they assume rather than prove the patient’s
actual drug intake, albeit that they cover longer periods of time.
On the contrary, direct methods (i.e., detection of the drug or a
metabolic product in a biologic ﬂuid) prove that a dose of a drug
was taken but cover brief medication periods. With the emergence
of microprocessor technologies in the 1990s, the precise timing of
medication-taking behavior with oral solid forms became feasible,
and revealed a comprehensive picture of an individual’s day-to-
day drug intake that neither drug serum concentrations nor pill
counts would have identiﬁed. Although electronic compliance-
monitoring devices (ECMD) are considered to provide the most
accurate and valuable data (Hughes, 2007) and are close to a “gold
standard” in measuring adherence, they have been mainly used
until now as a research tool, owing to their prohibitive cost. Elec-
tronicmonitoring is used in research areas tomeasure adherence in
population or in clinical studies; to assess determinants of adher-
ence, and to evaluate the effects of intervention on adherence. On
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the patient level, electronic monitoring allows to calculate dosing
intervals, taking and timing adherence; to identify speciﬁc pat-
terns of medication use including week-end effects, drug holidays
(discontinuing medication use for 24–72 h), toothbrush effect or
white-coat adherence (increasing adherence several days prior to
a medical appointment), and dumping (intentionally discarding
medication); to identify days of under- and over-consumption; to
link the timing of doses with the efﬁcacy of the drug and with
critical health incident (Riekert and Rand, 2002); to distinguish
between probable and improbable drug reactions or side effects
(Rudd, 1993; Riekert and Rand, 2002), and ﬁnally to give patients
insight into their own dosing history. The ECMD use a micro-
processor embedded in a pill bottle cap or in a storage container
(Haberer et al., 2012), that records the precise date and time, every
instance that the device is opened and closed. The major drawback
of the bottle is that itmonitors only one leaddrug and thus requires
one cap per medication, while the container holds up to 1-month
supply of different pills in its ﬁve inner compartments. Due to this
setting, data are missing on what was done at each opening; was
it to take one or more pills, to remove daily pocket doses or to ﬁll
a weekly organizer? (Samet et al., 2001). Further, both devices do
not accommodate the use of pillboxes (Hayes et al., 2006).
The new technology is composed of printed electronics made
of a clear, self-adhesive polymer ﬁlm with loops of conductive
wires that can be afﬁxed to blister packagings. The smart com-
ponents measure the electrical resistance and record the time of
its changes when a loop is broken, i.e., when a cavity is emptied.
The data are transferred via a wireless communication device to a
web-based database. This new technology was ﬁrst developed to ﬁt
commercially available standard blister packs (Jekle and Krämer,
2008), avoiding the transfer of pills into an ECMD and keeping the
primary packaging. We developed further the electronic ﬁlm tech-
nology to ﬁt on the rear side of a disposable multidose punch card
(Figure 1). This “unit-of-use packaging” consists of sealed calen-
dar compartmentswith severalmedications to be taken together in
ﬁxed combination, thus avoiding patients from having to use mul-
tiple medication packs and bottles. Currently, multidose punch
cards are ﬁlled manually by a host of community pharmacists, e.g.,
in the UK, Switzerland, Germany, France, Canada, and Australia.
With the electronicﬁlmapplied to amultidosepunch card, an indi-
vidualized polytherapy canbemonitored bymeans of the so-called
Polymedication Electronic Monitoring System (POEMS).
The purpose of this paper is to present an illustrative case using
a new technology of electronic adherence measurement of multi-
ple medication regimens with oral solid forms, and to estimate the
possible implications linked to this novel technology. We present
a preliminary report with one patient experience.
MATERIALS AND METHODS
EXTENDED CASE REPORT
Our patient is a single, recently retired, 65-year-old, Caucasian
male. He lives independently (and alone) in an apartment in a
medium-sized Swiss city and is in possession of a valid driver’s
license. He did have a history of alcohol abuse 20 years previously,
which he was able to overcome. Epilepsy was diagnosed in 1974
and is currently controlled with levetiracetam 1000 mg twice daily.
He is prescribed paroxetine 20 mg once daily for the treatment of
social phobia and relapsing depression. Persisting, slightly asymp-
tomatic anemia has been repeatedly investigated without conclu-
sive diagnosis. Probationary treatment with a vitamin B complex
FIGURE 1 | (A) Front side of a commercially available multidose punch card (Pharmis GmbH, Beinwil am See, Switzerland) with 7 × 4 cavities pre-ﬁlled with a
patient’s individualized medication regimen. (B) Rear side covered with an electronic ﬁlm of conductive tracks, a battery and an antenna, and a microchip
housing (Confrérie Clinique S.A., Lausanne, Switzerland).
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twice daily since October 2010 led to a partial correction of the
anemia. Rosuvastatin 20 mg and low-dose Aspirin 100 mg were
prescribed once daily for secondary prevention after a cardiovas-
cular incident. Hypothyroidism was picked up in March 2011 and
is being treated with levothyroxine 0.1 mg once daily. Zolpidem
10 mg once daily is being taken when required for difﬁculty sleep-
ing. The patient was brieﬂy hospitalized in May 2010 for break-
through seizures. His physician was suspecting non-adherence
with anti-epileptic drugs, while his pharmacist suspected an over-
consumption of sleeping pills because the patient would regularly
come between the regular reﬁll times, requiring additional zolpi-
dem tablets. Since hospital discharge, the patient was using a pill
organizer, reﬁlled weekly by his community pharmacist.
The patient was offered by his physician in August 2010 to get
his medication intake monitored, and he accepted. The pharma-
cist repackaged the entire regimen in aweekly 7× 4-cavities punch
card with POEMS, with six pills in the morning cavity (levothy-
roxine, rosuvastatin, Aspirin, paroxetine, vitamin B complex,
and levetiracetam), two pills in the evening cavity (vitamin B
complex and levetiracetam) and one pill for sleep disorder in the
bedtime cavity (zolpidem). The noon cavity was left emptied. The
remainder of the patient’s monthly medication was stored at the
study center to ensure that no other medication would be taken
beside that prescribed and individually blistered. The patient was
informed of the electronic monitoring system and was advised to
take his drugs as instructed by his physician.
The following parameters were derived from the electronic
reports, where “dose” is deﬁned as “unit-of-use drugs” included
in one cavity, according to the therapy plan.
(a) Percentage overall taking adherence (total doses taken divided
by total number of prescribed doses) calculated over the
duration of the observational period;
(b) Percentage of correct dosing days (days taking prescribed dose
divided by total days of prescribed dose) calculated over the
duration of the observational period;
(c) Percentage of correct dosing intervals (number of correct dos-
ing intervals divided by total number of prescribed dosing
intervals) calculated over the duration of the observational
period; a dosing interval is deﬁned as correct if the time
between doses is within 25% of the prescribed dosing interval
(±6 h for a 24-h period and ±3 h for a 12-h period).
RESULTS
Laboratory data at baseline showed no abnormalities beside a mild
normochromic andnormocytic anemia [hemoglobin 132 g/l (nor-
mal 140–180 g/l); red blood cells 4.35 T/l (normal 4.5–5.5 T/l)].
The very low cholesterol level [2.9 mmol/l (normal<5.0 mmol/l)]
suggested that the patient was taking his lipid lowering agent well.
The ﬁrst weekly report of the monitored pill intake is given in
Figure 2. The patient started his daily activities around noon.
Median intake hours, mean intervals between doses, and adher-
ence parameters are given inTable 1. As intervals betweenmorning
FIGURE 2 | Adherence report over 1 week after inclusion (August 2010).
The electronic punch card was handed out on Friday morning, with the ﬁrst
cavity to be opened on the Friday evening. The spots (see graph) reﬂect a
pushing through of all drugs contained in one distinct cavity as recorded
with date and time (see table) by the electronic wires in the ﬁlm.
Morning and evening doses are highlighted. Bedtime doses could
be taken when needed. Key: ™◦ ◦, morning doses; ›◦ ›, evening doses; ◦Õ,
bedtime doses.
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and evening doses were skewed compared to the theoretical 12-h
dose interval for a twice daily intake, the percentage of correct
dosing intervals for drugs contained in morning and evening
doses, such as levetiracetam (intake ±3 h every 12 h) was 0%.
The opening times of the bedtime cavities containing the sleep-
ing pills showed a doubling of the dose during the ﬁrst days of
the week, leaving the patient without sleeping pills for the rest of
the week.
A measurement-guided medication management (MGMM)
program (Hughes, 2007) was implemented by the physician after
viewing the records of the polymedication adherence monitoring.
Providing patients with feedback of their dosing histories has been
shown to positively modify adherence behavior, either with cue-
dose training (Rosen et al., 2004) or by raising awareness of the
implications of current behavior (de Bruin et al., 2005). Thus, an
intervention using elements of the ACE-ME model (assessment,
collaboration, education, monitoring, and evaluation; Gould and
Mitty, 2010) was planned with the pharmacist. The method of
motivational interviewing (Miller and Rollnick, 2009) should be
used by the pharmacist, i.e., open-ended questions, reﬂective lis-
tening, afﬁrmation, and summarization to help the patient express
his concerns about the behavioral change, enhance his personal
motivation, set goals and arrive at a change of plan. The planned
intervention should focus on the distorted dosing intervals. The
objective of the intervention should be the improving of the
patient’s timing adherence. After the ﬁnal preparations were made,
a session of 2 h was scheduled for the intervention and took place
at the community pharmacy on Thursday, December 16, 2010.
The reports of the intake pattern were printed out and discussed
with the patient. The patient was instructed that paroxetine needs
to be taken in the morning because of possible activating side
effects, such as nervousness or difﬁculty sleeping, which are unde-
sirable in the evening. A second aspect was the twice daily intake
of the immediate release tablets: levetiracetam. The pharmacist
explained that intake 12 h apart would result in constant plasma
concentrations, whilst minimizing concentration-related adverse
effects, such as hostility/aggression, anxiety, insomnia, and ner-
vousness/irritability (European Medicine Agency (EMA), 2009).
The patient should start on the next day morning with the new
intake behavior he agreed on.
The records of the next 14 days subsequent to intervention
are shown in Figure 3. A punch card was handed out every
Thursday afternoon, with the ﬁrst cavity to be opened on the
Friday morning. The last visit was scheduled for the morning of
Thursday, December 30. Overall taking adherence after interven-
tion was 102.5% due to the anticipated consumption of sleeping
pills before the last visit (Table 1). Time lapse between the 14
morning doses was close to the theoretical 24 h. The morning–
evening and evening–morning intervals were close to 12 h and
showed a higher constancy than before the intervention. As a
consequence, the percentage of correct dosing intervals for drugs
contained in morning and evening doses, such as levetiracetam
(every 12 ± 3 h) reached 42.3% compared to 0% before interven-
tion. The physician received the records, discussed them with the
patient at the next visit, prescribed a double-dose of the sleep-
ing pills and planed another session with the pharmacist aimed at
motivating further the patient to persist in keeping his new intake
pattern.
DISCUSSION
We present a new and innovative ﬁlm technology for monitoring
adherence to multiple medication by means of a single case of a
patient implementing a complex dosing regimen. To the best of
our knowledge, this is the ﬁrst time that drug intake patterns of an
entire pharmacotherapy, scheduled at 8:00 am, 8:00 pm, and bed-
time, have been monitored accurately and objectively in real-time.
The problems suspected overmonths by the treating physician and
the community pharmacist in the reported case (seizures due to
insufﬁcient adherence, over-consumption of sleeping pills) could
not be solved satisfactorily with the measures then at disposition,
like dispensing the medication in a pillbox. Only the electronic
monitoring of the entire pharmacotherapy revealed the irregular
Table 1 | Intake times, intervals between doses, and adherence parameters for the two periods of adherence monitoring before (August 2010)
and after (December 2010) the individualized intervention.
Before intervention
(7 days in August 2010)
After intervention
(14 days in December 2010)
Time of intake in the morning 8:00 am (median; interquartile range) 2:00 pm (10 h 42 min) 5:29 am (6 h 08 min)
Time of intake in the evening 8 pm (median; interquartile range) 6:40 pm (2 h 49 min) 7:09 pm (2 h 38 min)
Intervals between morning doses (mean ± SD) 21 h 51 min ± 5 h 23 h 53 min ± 7 h 31 min
Intervals between evening doses (mean ± SD) 24 h 50 min ± 1 h 15 min 24 h 03 min ± 3 h 10 min
Intervals between morning and evening doses (mean ± SD) 6 h 57 min ± 6 h 34 min 11 h 28 min ± 4 h 28 min
Intervals between evening and morning doses (mean ± SD) 16 h 07 min ± 7 h 28 min 12 h 25 min ± 5 h 59 min
Overall taking compliance 100% 102.5%
Correct dosing days* 100% 100%
Correct dosing intervals morning, e.g., acetylsalicylic acid (24 ± 6 h) 83.3% 53.8%
Correct dosing intervals morning and evening, e.g., levetiracetam (12 ± 3 h) 0% 42.3%
*Without optional bedtime doses.
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FIGURE 3 | Adherence report over 2 weeks after the intervention
(December 2010).The y -axis reﬂects local time after adjusting for wintertime
(−1 h). A punch card was handed out every Thursday afternoon, with the ﬁrst
cavity to be opened on the Friday morning. Morning and evening doses are
highlighted. Bedtime doses could be taken when needed. Key: ™◦ ◦, morning
doses; ›◦ ›, evening doses; ◦Õ, bedtime doses.
pattern of the medication intake and the selective consumption of
sleeping pills. The pattern would have remained undiscovered if
only one lead drug had been tracked, e.g., with an electronic pill
cap; and even unsuspected if the tracked drug had to be taken in
the evening (mean interval between evening doses: 24 h 50 min).
A personalized and targeted intervention could only be set up
after the health professionals were aware of the distorted medi-
cation use. Thus, POEMS could guide health professionals when
they optimize the treatment of patients whose unsatisfactory clin-
ical outcome is suspected to depend on insufﬁcient adherence
behavior. This new technology could thus ﬁnd its place in ambu-
latory care, e.g., in speciﬁc patients when physicians suspect any
form of deviant adherence, as well as in clinical trials, e.g., with
critical drugs or expensive drugs, when non-adherence must be
excluded with strong certainty. The actual costs of the multidose
punch cards are low (around 2 for one punch card), and the
Swiss health insurance reimburse the adherence aid delivered by a
community pharmacist as a cognitive service. The electronic ﬁlm
as research prototypes are at a high price, that will decrease as
soon as the production can be automated, and reach an affordable
price.
One limitation inherent to the electronic monitoring of med-
ication use is that the patient gets no other medication than the
individually repackaged drugs, in order to prevent any extra med-
ication intake that would not be recorded. The lack of medication
stock as well as the obligation to have punctual reﬁlls might be
a constraint too strong for some patients and might represent a
selection bias in larger studies. However, some patients welcome
the simpliﬁcation obtained with one multidrug punch card and
the suppression of the different primary packagings. Further, some
patients may be reluctant to use this technology because they may
feel under surveillance. However, when the monitoring is not pre-
sented as a supervision but as a way to treatment optimization, one
can suppose that the patients will accept an electronic monitoring.
We observed also a marked curiosity from our patient as well as a
certain desire to compete with the technique.
When searching for a gold standard for adherence monitoring,
electronic ﬁlms afﬁxed to multiple medication punch cards appear
to ﬁll all the criteria, i.e., they are non-invasive, unobtrusive, objec-
tive, and user friendly. In addition, the transparent compartments
on the front side facilitate visual veriﬁcation of the pre-ﬁlled medi-
cation and contribute to the safety of drug intake. The monitoring
of a multiple drug regimen depicts the intake times of all drugs
and thus, enables to evaluate complex drug–effect relationship like
drug resistance and drug–drug interactions. Finally, the new sys-
tem is usable, even when a patient is used to storage devices like a
pillbox.
Some studies showed that short message services (SMS) sent
automatically to patients at the appropriate time without interfer-
ence of a healthcare professional have positive effects on adherence
rate (Vervloet et al., 2012). Further, ﬁrst results with transmis-
sion of adherence data through telephone connection in real-time
showed the feasibility of the immediate monitoring and its poten-
tial to give feedback when a dose of a drug is not taken. Thus,
in the near future, one could imagine that medication adherence
data over the entire therapy plan would be available as soon as the
electronic wires are activated, so that a failure to take medication
could be detected immediately and intervention could be taken if
appropriate, like sending a SMS reminder. We are well aware that
we present a single case to depict new emerging ﬁelds of moni-
toring a polymedication. Further studies are needed to conﬁrm
the generalizability of our ﬁndings and to establish the place of
POEMS in ambulatory care and in clinical trials.
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